Elamipretide in Heart Failure

Methods
The canine model of intracoronary microembolization-induced chronic HF used in this study was previously described in detail. 20 Fourteen healthy mongrel dogs, weighing between 20.8 and 25.7 kg, underwent serial intracoronary microembolizations performed 1 to 2 weeks apart to produce HF. Embolizations were discontinued when LV ejection fraction (EF), determined angiographically, was ≈30%. The study was approved by Henry Ford Health System Institutional Animal Care and Use Committee and conformed to the National Institute of Health Guide and Care for Use of Laboratory Animals (National Institutes of Health publication No. . Six weeks after the last microembolizations, HF dogs were randomized to 3 months therapy with subcutaneous injections of elamipretide (0.5 mg/kg once daily, n=7, HF+ELA) or vehicle (normal saline, once daily, n=7). Vehicle-treated HF dogs served as controls (HF-CON). Intravenous elamipretide has a half-life of 4 hours in dogs, and it is 100% renally excreted with 99% recovery in urine 24 hours after administration. Elamipretide's peak plasma concentration is 325 ng/mL at 1 hour post dosing at 0.05 mg/kg. In all dogs, hemodynamic, ventriculographic, echocardiographic, and Doppler measurements were made at baseline, before treatment (pretreatment) and repeated 3 months after initiating treatment (post-treatment). For more details on the methods in this study, please see Data Supplement.
To gain further insight into the mechanism of action of elamipretide, we also examined the acute effects of intravenous elamipretide on LV function. In this acute study, 12 HF dogs were randomized to a 2 hour infusion of elamipretide (0.05 mg/kg per hour, n=7) or to a 2 hour infusion of v/v of normal saline (control, n=5).
Determination of Plasma Biomarkers and ROS
Plasma levels of interleukin-6, tumor necrosis factor-α, C-reactive protein, and n-terminal-pro brain natriuretic peptide were determined in EDTA plasma using the principle of the double antibody sandwich enzyme-linked immunosorbent assay with commercially available kits. 21 Total burden ROS in plasma was determined using the luminoldependent chemiluminescence assay and expressed as relative luminescence units (RLU)/mL. 22 
Histomorphometric Measurements in LV Tissue
After the final hemodynamic study and while under general anesthesia, the dog's chest was opened and the heart rapidly removed and LV tissue prepared for histological and biochemical evaluation. The volume fraction of replacement fibrosis and interstitial fibrosis, myocyte cross-sectional area, a measure of cardiomyocyte hypertrophy, capillary density, and oxygen diffusion distance were assessed histomorphometrically as previously described. 23, 24 LV tissue from 7 normal dogs was used for comparisons. Tissue sections were stained with Gomori trichrome to identify fibrous tissue. Cryostat sections stained with fluorescein-labeled peanut agglutinin were used to delineate cardiomyocyte border to measure myocyte cross-sectional area, and sections double-stained with rhodamine-labeled Griffonia Simplicifolia lectin I were used to measure capillary density and oxygen diffusion distance, the latter defined as half the distance between 2 adjoining capillaries.
Determination of Mitochondrial Function
The following mitochondrial function measures were assessed in freshly collagenase-isolated, digitonin-permeabilized cardiomyocytes: mitochondrial state-3 respiration was measured using a Clarktype electrode (Strathklein Respirometer). 6 Mitochondrial membrane potential (Δψm) was measured using the commercially available JC-1 cationic fluorescent dye kit (Sigma, St. Louis, MO). This assay is an indicator of mitochondrial potential which, in presence and absence of valinomycin, exhibits potential-dependent accumulation in mitochondria, as indicated by a fluorescence emission shift from green (495ex/534em) to red (495ex/590em). 7 mPTP opening was assessed using calcein. 7 The rate of calcein exit through mPTP was measured by recording the fluorescence signal every 2 minutes and calculated as a percent change from maximal fluorescence signal. Mitochondrial maximal rate of ATP synthesis and the ratio ATP/ADP were determined using the ApoSENSOR ADP/ATP ratio bioluminescent assay kit (BioVision, Milpitas, CA). 7 This assay uses the enzyme luciferase to catalyze the formation of light from ATP and luciferin. The effects of an in vitro 1 hour incubation of isolated cardiomyocytes from 3 untreated HF dogs with varying concentrations of elamipretide (0.0, 0.01, 0.1, 1.0 μM) on mitochondrial state-3 respiration was also examined. ADP-stimulated respiration was determined in aliquots of 10 μL gravity-settled cardiomyocytes.
Determination of Mitochondrial Complex I and IV Activities
The activity of mitochondrial complex-I was assayed spectrophotometrically in mitochondrial membrane fractions obtained from LV anterior wall. 25 Complex-I activity was calculated as the rotenonesensitive NADH:ubiquinone oxidoreductase activity and expressed as nmoles/min per mg protein. The activity of mitochondrial complex-IV (cytochrome c oxidase) was determined polarographically Figure 1 . Top, Change Δ (treatment effect) between pretreatment and 2 hour intravenous infusion of elamipretide on left ventricular (LV) end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF), and stroke volume (SV) in untreated heart failure control dogs (HF-CON) and heart failure dogs treated with elamipretide (HF+ELA). Bottom, Change Δ (treatment effect) between pretreatment and 12 weeks post-treatment for LV EDV, ESV, EF, and fractional area of shortening (FAS) in HF-CON and HF+ELA dogs. Probability values are comparisons between HF-CON and HF+ELA dogs. Statistical significance based on t-statistic for 2 means. All bar graphs are depicted as mean±SEM.
in mitochondrial membrane fractions 25 and expressed as nmoles molecular oxygen/min per mg protein.
Determination of Abundances of Key Subunits of Complex-I, -II, -III, -IV, and -V
Abundance of key subunits of mitochondrial complexes was determined by Western blotting using the Total OXYPHOS Antibody Cocktail ab110413 (abcam, Cambridge, MA) and bands quantified in densitometric units (du). The subunits were as follows: complex-I subunit NDUFB8; complex-II succinate dehydrogenase subunit B; complex-III subunit Core 2; complex-IV subunit I, and complex-V ATP synthase subunit a.
Western Blotting and Measurements of Cardiolipin and ROS
Western blotting was used to quantify changes in LV tissue levels of specific mitochondrial functions/dynamics and signaling proteins. Western blots were performed using primary antibodies and horse radish peroxidase-coupled secondary antibodies. Protein bands were visualized by chemiluminescence reagents (Thermo Scientific, Pittsburg, PA). Proteins included endothelial nitric oxide synthase, inducible nitric oxide synthase, peroxisome proliferator-activated receptor coactivator-1α, cytosolic cytochrome c, active caspase 3, sarcoplasmic reticulum Ca 2+ -ATPase (SERCA-2a), and β-actin as internal control. Protein bands were quantified in du.
Total cardiolipin and tetralinoleol cardiolipin [(18:2) 4 CL] species were measured using electrospray ionization mass spectroscopy 26 and quantified in nmol/mg of noncollagen protein. Total cardiolipin and (18:2) 4 CL were normalized to LV mitochondrial protein levels and quantified as nmol cardiolipin/mg of mitochondrial protein. Total ROS in LV tissue was determined using the luminol-dependent chemiluminescence assay and expressed in RLU/μg protein. 22 In addition to total ROS, 4-hydroxynonenal, a natural biproduct of lipid peroxidation Ai indicates time-velocity integral representing left atrial contraction; CI, cardiac index; CO, cardiac output; DT, deceleration time of early mitral inflow velocity; EDWS, LV end-diastolic circumferential wall stress; Ei, time-velocity integral of the mitral inflow velocity waveform representing early filling; Ei/Ai, ratio of Ei to Ai; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; mAoP, mean aortic pressure; SV, stroke volume; and SVR, systemic vascular resistance. All data are mean±SEM. P value is probability value between HF-CON and HF+ELA. Values <0.05 are considered significant. and capable of binding to proteins and forming stable adducts, was also measured using the commercially available Oxiselect HNE-His Adduct ELISA Kit (Biolabs, Inc, San Diego, CA).
Statistical Analysis
Within-group comparisons of hemodynamic, ventriculographic, echocardiographic, Doppler, and plasma biomarker measures were made using repeated measures analysis of variance with alpha set at 0.05. If significance was attained, pairwise comparisons between baseline, pretreatment, and post-treatment measures were made using the Student-Neuman-Keuls test with P<0.05 considered significant. To assess treatment effect, the change (Δ) in each measure from pretreatment to post-treatment within each study arm was calculated and the Δs compared between the 2 groups using a t-statistic for 2 means with P≤0.05 considered significant. Histological and biochemical measures between normal, HF-CON, and HF+BEN dogs were compared using 1-way analysis of variance with alpha set at 0.05. If significance was attained by analysis of variance, pairwise comparisons were performed using the Student-Neuman-Kuels test with P<0.05 considered significant. All the data exhibited normal distributions, and nonparametric testing led to similar results. Data are reported as mean±standard error of the mean.
Results
Effects of Acute Intravenous Infusion of Elamipretide
Compared with intravenous saline, intravenous elamipretide had no effect on heart rate (HR), mean aortic pressure (mAoP), or systemic vascular resistance (SVR). Elamipretide had no effect on LV end-diastolic volume but significantly decreased end-systolic volume and significantly increased EF and stroke volume ( Figure 1 ).
Chronic Studies With Subcutaneous Elamipretide
Within-Group Changes in Hemodynamics and Plasma Biomarkers
Hemodynamic, ventriculographic, echocardiographic, Doppler, and plasma biomarker results are shown in Table 1 . There were no significant differences between the 2 study groups in any measures obtained at baseline or at pretreatment. In the HF-CON, HR, mAoP, LV end-diastolic pressure, stroke volume, cardiac output, cardiac index, SVR, ratio of time-velocity integral of early mitral inflow velocity and time-velocity integral during left atrial contraction (Ei/Ai), deceleration time of early mitral inflow velocity, and LV circumferential end-diastolic wall stress did not change significantly over the course of 3 months of follow-up compared with pretreatment values ( Table 1 ). In the HF+ELA, HR and mAoP were also not significantly changed during therapy. In this group, Ei/Ai and deceleration time of early mitral inflow velocity tended to increase but not significantly compared with pretreatment values (Table 1) . Therapy with elamipretide significantly increased stroke volume, cardiac output, and cardiac index and decreased end-diastolic pressure, SVR, and end-diastolic wall stress.
In HF-CON, end-diastolic volume and end-systolic volume tended to increase and EF tended to decrease at posttreatment compared with pretreatment (Table 1 ). In HF+ELA, end-diastolic volume was unchanged, end-systolic volume tended to decrease, and EF increased significantly (Table 1) . Plasma levels of n-terminal pro-brain natriuretic peptide, interleukin-6, tumor necrosis factor-α, C-reactive protein, and ROS significantly increased in HF-CON compared with normal dogs. Treatment with elamipretide significantly reduced levels of all 5 biomarkers to near normal levels. In HF-CON, plasma levels of all 5 biomarkers remained markedly elevated throughout the treatment phase (Tables 1).
Between-Group Changes in Hemodynamics and Plasma Biomarkers (Treatment Effect)
Between-group comparisons of the change (Δ) between pretreatment and post-treatment measurements are shown in Table 2 and Figure 1 . Compared with HF-CON, long-term therapy with elamipretide had no effect on HR, mAoP, and SVR but tended to increase stroke volume and decrease enddiastolic volume and end-systolic volume. Treatment with Figure 2 . Change Δ (treatment effect) between pretreatment and 12 weeks post-treatment for plasma levels of n-terminal pro brain natriuretic peptide (nt-pro BNP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), c-reactive protein (CRP), and reactive oxygen species (ROS). Probability values are comparisons between heart failure control dogs (HF-CON) and elamipretide-treated heart failure dogs (HF+ELA). Statistical significance based on t-statistic for 2 means. All bar graphs are depicted as mean±SEM. elamipretide significantly increased EF, cardiac output, cardiac index, and LV fractional area of shortening. Measures of LV diastolic function also tended to improve with elamipretide as evidenced by a decrease of end-diastolic pressure and enddiastolic wall stress and a trend for an increase in Ei/Ai and deceleration time of early mitral inflow velocity. Compared with HF-CON, elamipretide significantly decreased plasma levels of n-terminal pro-brain natriuretic peptide, interleukin-6, tumor necrosis factor-α, C-reactive protein, and ROS to near normal levels ( Figure 2) .
Histomorphometric Findings and Tissue ROS
Compared with normal dogs, HF-CON dogs showed significant increases in volume fraction of replacement fibrosis, volume fraction of interstitial fibrosis, oxygen diffusion distance, and myocyte cross-sectional area and a decrease in capillary density (Table 3) . Elamipretide significantly reduced volume fraction of interstitial fibrosis, oxygen diffusion distance, and myocyte cross-sectional area and increased capillary density. The volume fraction of replacement fibrosis also tended to decrease but did not reach statistical significance. Total ROS in LV tissue was significantly higher in HF-CON compared with normal dogs and decreased to near normal in HF+ELA ( Table 4 ). Levels of 4-hydroxynonenal adducts were (Table 4) .
Mitochondrial Function
Mitochondrial state-3 respiration, Δψm, maximum rate of ATP synthesis, and ATP/ADP ratio were all decreased in HF-CON compared with normal dogs (Figure 3 ). Treatment with elamipretide significantly increased all measures to near normal levels (Figure 3 ). The rate of calcein exit was significantly slower in HF+ELA dogs compared with HF-CON (Figure 3) , indicative of reduced opening of the mPTP. Complex-I and complex-IV activities were significantly reduced in HF-CON compared with normal dogs (Figure 4 ). Elamipretide significantly increased enzymatic activities of both complexes to near normal levels (Figure 4) . In all instances, the observed improvements in mitochondrial function parameters after treatment with elamipretide trended toward baseline (normal state) and at no time exceeded normal levels, indicating that full recovery of mitochondrial function was not necessary to achieve the degree of observed hemodynamic improvement.
In vitro incubation of isolated cardiomyocytes from untreated HF dogs with increasing concentration of elamipretide showed a concentration-dependent improvement in state-3 respiration. In the absence of elamipretide, ADP-stimulated respiration was 248±9 nAtom O/min per mg protein and increased to 303±33 at 0.01 μmol/L, to 405±39 at 0.1 μmol/L, and to 371±28 at 1.0 μmol/L concentration of elamipretide.
Proteins That Modulate Mitochondrial Function
There were no differences in protein level of the internal control β-actin between normal dogs (0.44±0.05 du) and HF-CON (0.41±0.04 du) or elamipretide-treated HF dogs (0.45±0.04 du). Proteins that regulate mitochondrial biogenesis and respiration were dysregulated in HF-CON compared with normal dogs ( Figure 5 ). Compared with normal, levels of endothelial nitric oxide synthase and peroxisome proliferator-activated receptor coactivator-1α were significantly decreased in HF-CON, whereas inducible nitric oxide synthase was significantly upregulated. Elamipretide normalized levels of both nitric oxide synthase isoforms and peroxisome proliferator-activated receptor coactivator-1α ( Figure 5 ). Cytosolic levels of cytochrome c were significantly increased in HF-CON as were tissue levels of active caspase-3. Treatment with elamipretide normalized the expression of both proapoptotic proteins ( Figure 5 ). Compared with normal, HF-CON dogs had significantly lower levels of SERCA-2a, which was significantly increased to near normal by elamipretide ( Figure 5 ). Total cardiolipin and total cardiolipin normalized to mitochondrial protein were significantly decreased in LV of HF-CON compared with normal dogs as were the levels of total (18:2) 4 CL subspecies and total (18:2) 4 CL subspecies normalized to mitochondrial protein. Treatment with elamipretide significantly increased all measures to near normal levels ( Figure 6 ). Protein levels of key subunits of mitochondrial complexes I-V decreased significantly in HF dogs compared with normal dogs (Figure 7 and Table 4 ). Treatment with elamipretide partially restored normal levels of all key subunits. Compared with untreated controls, levels of subunits of complexes I, II, and IV improved significantly after long-term therapy with elamipretide, whereas the observed improvement in subunits of complexes III and V did not reach statistical significance (Figure 7 and Table 4 ). In all instances, the observed improvements in protein levels after treatment with elamipretide trended toward baseline (normal state) and at no time exceeded normal levels.
Discussion
The results indicate that long-term monotherapy with elamipretide improves LV function and prevents progressive LV enlargement. The magnitude of improvement is similar to that observed in this canine HF model after longterm therapy with angiotensin-converting enzyme inhibitors and β-blockers. 27 Improved LV function was associated with reductions in plasma biomarkers of natriuretic peptides and proinflammatory cytokines and was not associated with significant changes in HR, mAoP, or SVR. These benefits occurred alongside normalization of mitochondrial function evidenced by improved rate of ATP synthesis and reduced ROS formation. Elamipretide also attenuated structural LV remodeling evidenced by reduction of cardiomyocyte hypertrophy and interstitial fibrosis and increased capillary density. 23, 24, 28 Normalization of these structural components likely promotes greater LV compliance and tissue oxygenation and hence improved passive LV filling and overall LV function. The improvements in histomorphometric measure of structural remodeling after treatment with elamipretide are similar in magnitude to those seen in this canine HF model after monotherapy with AT1 receptor antagonists and β-blockers. 29, 30 In this study, chronic treatment with elamipretide improved energy availability in the failing myocardium evidenced by increased maximum rate of ATP synthesis and increased ATP/ ADP ratio. In addition to improving mitochondrial state-3 respiration and mitochondrial membrane potential and reducing opening of the mPTP, treatment with elamipretide also normalized the activity of complex-I and complex-IV while limiting the formation of ROS. Improved ATP synthesis by mitochondria can also lead to improved sarcoplasmic reticulum calcium cycling by increasing SERCA-2a activity. Reduced SERCA-2a activity and expression are key maladaptations in HF. Treatment with elamipretide was associated with improved protein levels of SERCA-2a.
The improvement in mitochondrial function after longterm therapy with elamipretide leads to normalization of cardiolipin. The latter is likely facilitated by the ability of elamipretide to permeate the outer mitochondrial membrane and bind to cardiolipin, a signature phospholipid of the inner mitochondrial membrane that plays an important role in cristae formation, activity of respiratory complexes, organization of the respiratory complexes into supercomplexes for oxidative phosphorylation, mitochondrial fusion, and mitochondrial DNA stability and segregation. [10] [11] [12] 14, 31 Cardiolipin is biosynthesized in a series of steps from phosphatidic acid and remodeled into a form which contains 4 18:2 fatty acid chains, (18:2) 4 CL. Cardiolipin peroxidation and depletion have been reported in a variety of pathological conditions associated with energy deficiency. 14 In the present study, total cardiolipin and (18:2) 4 CL were decreased in LV myocardium of dogs with HF and treatment with elamipretide normalized total cardiolipin and (18:2) 4 CL. The decrease in cardiolipin was driven by changes in the lipid structure on the inner mitochondrial membrane because of peroxidation and not necessarily a reflection of changes in the total LV myocardial pool of Nevertheless, additive beneficial effects of elamipretide on mitochondrial biogenesis/turnover may also coexist alongside membrane remodeling. Cardiolipin is essential for activity of mitochondrial complexes and, in particular, complex I and complex-IV. Defects of complex I are integral to the formation of ROS, whereas complex-IV is essential for oxidative phosphorylation. In the present study, elamipretide normalized the activity of complex-I and -IV, a finding consistent with normalization of cardiolipin. Elamipretide also restored, albeit in part, levels of key subunits of mitochondrial complexes I through V and reduced the formation of ROS in LV myocardium. Preserving cardiolipin is also important in respiratory function through supercomplex assembly. Even though supercomplex expression was not measured in the present study, others have shown that elamipretide preserves supercomplexdependent mitochondrial function in LV myocardium of rats subjected to ischemia-reperfusion injury. 32 Even though the primary objective of this study was to evaluate the chronic effects of elamipretide, we also showed that a short-term (2 hours) intravenous infusion of elamipretide improved LV systolic function and that in vitro incubation of failing canine cardiomyocytes in increasing concentration of elamipretide elicits improvement in ADPdependent (state-3) mitochondrial respiration. These results indicate that elamipretide can elicit short-term benefits on LV function possibly through improved mitochondrial function as evidence by improved respiration. The data also suggest that an improvement in the abundance of 18:2 cardiolipin is not required in the short term for enhancement of mitochondrial function by elamipretide. It is not likely that novel synthesis and remodeling of cardiolipin can occur in a short 2 hour span of elamipretide infusion. It is possible, although remains to be shown, that the electrostatic interaction between elamipretide and cardiolipin is itself sufficient to stabilize the complexes on the electron transport chain and, in doing so, improve efficiency of the electron transfer culminating in reduced ROS and enhanced oxidative phosphorylation. This explanation is supported by studies of old mice with mitochondrial dysfunction, 33 in which resting and maximal mitochondrial ATP production and cell energy state (phosphocreatine/ATP) were rapidly reversed only 1 hour after injection of elamipretide. 33 Mitochondria are a major source of ROS production. Excess ROS formation can lead to tissue injury, cardiomyocyte degeneration, and programmed cell death. Increased ROS can contribute to increased opening of the mPTP 34 and has been shown to interact with calcium signaling and several ion channels involved in cardiac hypertrophy signaling and its progression to HF. 35, 36 We previously showed that HF is associated with opening of the mPTP with an attendant increase in the level of cytochrome c in the cytosol and consequently an increase in cardiomyocyte apoptosis. 7, 8, 37 In the present study, long-term therapy with elamipretide reduced ROS formation, attenuated mPTP openings, and significantly decreased the levels of cytosolic cytochrome c and active caspase-3, thus suppressing a major signaling pathway for apoptosis. Levels of plasma proinflammatory cytokines were reduced in the present study after chronic treatment with elamipretide. We are not aware of any evidence that elamipretide acts directly as an anti-inflammatory. It is more likely that by reducing excessive ROS formation, elamipretide limits tissue injury and, in doing so, attenuates proinflammatory cytokines.
In conclusion, this is the first study to our knowledge where the effects of long-term therapy with elamipretide were evaluated in a chronic model of HF. The results support the hypothesis that targeting mitochondrial dysfunction in HF is key to improving overall LV function. Elamipretide represents a new class of compounds that can improve the availability of energy to failing heart and reduce the burden of tissue injury caused by excessive ROS production. In doing so, elamipretide limits end-organ damage and ensures the production of energy commensurate with the needs of the myocardium for improving cell function and overall LV performance.
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